Kanglaite - Zhejiang Kanglaite Pharmaceutical/KangLaiTe USA

Drug Profile

Kanglaite - Zhejiang Kanglaite Pharmaceutical/KangLaiTe USA

Alternative Names: Kanglaite gelcap; Kanglaite injection; KLT; KLTc; KLTi

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KangLaiTe USA; Zhejiang Kanglaite Pharmaceutical
  • Class Antineoplastics; Herbal medicines; Traditional-Chinese-medicine
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants; Cell cycle inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Cancer; Liver cancer; Non-small cell lung cancer
  • Phase II Pancreatic cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cachexia in USA (IV, Injection)
  • 19 Aug 2015 Phase-II development for Pancreatic cancer and Prostate cancer is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top